Hip Viscosupplementation: What is the Best Dosage? (Hip VS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Gustavo C de Campos, MD
- Phone Number: +551983318000
- Email: gustavoccampos@terra.com.br
Study Contact Backup
- Name: Marcia U Rezende, PhD
- Phone Number: +5511981226282
- Email: murezende@uol.com.br
Study Locations
-
-
SP
-
São Paulo, SP, Brazil, 05410-000
- Recruiting
- Instituto de Ortopedia e Traumatologia HC-FMUSP
-
Contact:
- Valquiria
- Phone Number: +551126616888
-
Principal Investigator:
- Marcia U Rezende, Phd
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Met the American College of Rheumatology criteria for hip osteoarthritis
- No hip intraarticular injections in the last 6 months
Exclusion Criteria:
- Severe reaction to the procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Articular Lavage
Patients from Group Zero will receive articular lavage with saline injection
|
Patients will receive articular lavage with saline injection
|
|
Experimental: Group 1
Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
|
Patients will receive articular lavage with saline injection
Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
Other Names:
|
|
Experimental: Group 2
Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
|
Patients will receive articular lavage with saline injection
Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
Other Names:
|
|
Experimental: Group 3
Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
|
Patients will receive articular lavage with saline injection
Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WOMAC
Time Frame: 6 months
|
Pain and function assessment with WOMAC questionaire
|
6 months
|
|
VAS
Time Frame: 6 months
|
Pain assessment with Visual Analogic Scale (VAS)
|
6 months
|
|
Lequesne
Time Frame: 6 months
|
Pain and function assessment with Lequesne questionaire
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gustavo C de Campos, MD, FMUSP
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0255/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.